SHANGHAI – Shenyang Sunshine Pharmaceutical Co. Ltd. (3SBio), a revenue-generating biotech with products in China, has decided to try its hand at the hottest category in immuno-oncology. The company will be responsible for developing three chimeric antigen receptor T cell (CAR T) candidates in Greater China (including Macao and Hong Kong) originally discovered by TNK Therapeutics Inc. (TNK), of San Diego. TNK, a cellular therapy company, is a subsidiary of Nasdaq-listed Sorrento Therapeutics Inc. (SRNE).